A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders

Medical Hypotheses

Volumn 69, Issue 2, 2007, Pages 338-340

  Yamagishi, S ^a   Nakamura, K ^a   Matsui, T ^a   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ALZHEIMER DISEASE; AMADORI REARRANGEMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPLEX FORMATION; CROSS LINKING; DEGENERATIVE DISEASE; DIABETIC ANGIOPATHY; GLYCATION; HEART PROTECTION; HEPATOMA CELL; HUMAN; HYPERCHOLESTEROLEMIA; MELANOMA; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PLEIOTROPY; POLYMERIZATION; PRIORITY JOURNAL; REACTION ANALYSIS; SIGNAL TRANSDUCTION; VASCULITIS;

DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES;

EID: 34249340134     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.11.054     Document Type: Article

References (15)

1. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 46 (1995) 223-234
2. Grandhee S.K., and Monnier V.M. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 266 (1991) 11649-11653
3. Yamagishi S., and Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
4. Takeuchi M., and Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 63 (2004) 449-452
5. Abe R., Shimizu T., Sugawara H., et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 122 (2004) 461-476
6. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., and Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23 (2003) 129-134
7. Schmidt A.M., and Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2 (2000) 430-436
8. Takeuchi M., and Yamagishi S. Alternative routes for the formation of glyceraldehydes-derived AGEs (TAGE) in vivo. Med Hypotheses 63 (2004) 453-455
9. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
10. Colhoun H.M., Betteridge D.J., Durrington P., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364 (2004) 685-696
11. Mason R.P., Walter M.F., Day C.A., and Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96 Suppl (2005) 11F-23F
12. Yamagishi S., Matsui T., and Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 12 (2006) 1549-1554
13. Yamagishi S., Nakamura K., Matsui T., Sato T., and Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 66 (2006) 1019-1021
14. Jinnouchi Y., Yamagishi S., Takeuchi M., et al. Atorvastatin decreases serum levels of advanced glycation end products in patients with type 2 diabetes. Clin Exp Med 6 (2006) 191-193
15. Yoshida T, Yamagishi S, Nakamura K, et al. Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation. Vascular Dis Prevention 2006 [in press].